Blaine
McKee

Blaine McKee is the president and chief executive of Walden Biosciences, a clinical-stage company a short walk from MIT in Cambridge, Massachusetts. Its ambition is unusually direct for an industry fond of incremental wins: build medicines that go after the kidney directly, rather than the standard playbook of slowing a patient's slide toward dialysis or transplant.

That framing is McKee's. As he puts it, more than ten percent of the world's population lives with kidney disease, and the therapies on the market only delay the inevitable without ever touching the organ they are meant to protect. Walden's whole reason for existing is to close that gap. The company was founded by renal experts who identified specific cells inside the kidney - podocytes and proximal tubule cells - as the place to intervene before the damage compounds.

McKee is well suited to translate that science into a business, because he has stood on both sides of the bench. He started his career as a research scientist at Gilead Sciences, then spent roughly fifteen years at Genzyme, the Cambridge biotech pioneer, where he rose to senior vice president of strategic development across the oncology, transplant, and multiple sclerosis divisions. Somewhere in that arc he stopped being only a scientist and became a dealmaker.

The corporate-development years

After Genzyme, McKee took the chief-business-officer chair at 480 BioMedical, then ran corporate development at Shire, where he led strategy, mergers and acquisitions, licensing, due diligence, and alliance management. He moved on to ImmunoGen as executive vice president and chief business officer, owning the company's transactional engine: deals, valuations, commercial assessment, and the management of partnerships. These are not glamorous jobs. They are the jobs that decide whether a biotech survives the gap between a promising molecule and a marketed drug.

What makes McKee unusual is the academic spine underneath all that business activity. He holds a bachelor's in chemistry from Colorado State University, a doctorate in organic chemistry from MIT, and a finance MBA from MIT's Sloan School of Management. Two MIT degrees, one in a wet lab and one in a spreadsheet. It is a combination that lets him follow both the mechanism and the term sheet in the same meeting, and it explains why he ended up founding a company rather than just advising one.

Building Walden

In 2020 McKee launched Walden Biosciences with a $51 million Series A led by ARCH Venture Partners and UCB Ventures. He used the money to do the unglamorous founding work: a brick-and-mortar lab in Kendall Square, the densest square mile of biotech on the planet, and a team he recruited past twenty-five people - executives, scientists, and operators pulled from the industry he had spent decades inside.

Walden's bet is hedged across two very different kinds of medicine. The first is WAL0921, a humanized antibody that inhibits suPAR, a circulating protein implicated in podocyte dysfunction. The second is WAL0623, a small molecule designed to restore the function of an enzyme called dynamin in the cells that filter the blood. One is a biologic, one is a small molecule, and they attack the same problem from opposite directions. For a first-time founder-CEO, running both at once is a statement of conviction.

The hard part isn't the biology

Ask McKee what keeps biotech leaders up at night and he points not at the science but at the money. In 2023 he named capital raising as the industry's biggest challenge, citing the political and economic uncertainty hanging over research and development funding. Coming from someone who spent a career inside corporate development, that is not pessimism - it is a clear-eyed reading of where the bottleneck actually sits. The molecules can be brilliant and still never reach a patient if the funding dries up.

By the end of 2024, Walden had completed the Phase 1 study of WAL0921 in healthy subjects, shown the drug rapidly reduced suPAR, and reported it was well tolerated. The company also wrapped the studies needed to take WAL0623 into humans. The 2025 plan reads like a founder's to-do list: launch the next cohort of the Phase 2 basket study in rare diseases such as FSGS and IgA nephropathy, start the first human study of the small molecule, deliver interim data, and - always - secure the capital to keep both programs moving.

Beyond Walden, McKee sits on the board of VBI Vaccines, where he chairs the audit committee, and he has previously served on the boards of BioStage, ArmaGen, and the New York Pharma Forum. It is the portfolio of someone the industry trusts to read a balance sheet and a clinical readout with equal fluency.

The throughline is consistency of purpose. McKee has been a bench scientist, a strategist, a dealmaker, a board director, and now a founder-CEO. Each role added a different lens, and Walden is what happens when one person points all of them at the same target: a kidney that current medicine has learned to manage but never to repair.